KCT0001693已完成未知
A randomized, open-label, 4-way crossover single dose clinical trial to investigate the pharmacokinetic interaction between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers
Hanmi Pharm0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •Healthy men
排除标准
- •Gastrointestinal disease affecting drug absorption
研究者
相似试验
招募中
1 期
A clinical trial to study the effect of SMC021 on the blood levels of ibuprofen and paracetamol and the effect of ibuprofen and paracetamol in blood levels of SMC021CTRI/2009/091/001052ovartis Healthcare Pvt Ltd56
已完成
不适用
A randomized, open-label, four-way cross-over, single dose study to compare the pharmacokinetics of monomethyl fumarate and other metabolites after administration of dimethyl fumarate as a delayed- and slow-release formulation of FP187 and Tecfidera® in healthy volunteers.10029305Multiple SclerosisNL-OMON42906Forward Pharma GmbH24
已完成
不适用
A phase I, open-label, randomized, 4-way crossover study in subjects with chronic Hepatitis B virus infection to assess pharmacokinetics (fasted/fed), safety, tolerability and pharmacodynamics of single oral doses of Farnesoid X receptor agonist EYP001a.Hepatitis Bviral infection of the liver10019654NL-OMON45541ENYO Pharma SA14
已完成
不适用
An open label, part-randomised, four-way crossover, single and repeat dose study to determine the dose proportionality and absolute bioavailability of fluticasone furoate (FF) when administered as FF inhalation powder from the novel dry powder inhaler in healthy subjects.chronic inflammation of the bronchial tubesshortness of breath10024970NL-OMON37181GlaxoSmithKline36
已完成
不适用
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of Canagliflozin when Administered as the Monohydrate form to the Hemihydrate form in Healthy Adult Subjects under Fasted Conditionsglucose-lowering therapyglycemic control10018424NL-OMON42409Janssen-Cilag44